Literature DB >> 30868316

Relationship between health care insurance status, social determinants and prevalence of diabetes-related microvascular complications in patients with type 1 diabetes: a nationwide survey in Brazil.

Marilia Brito Gomes1, Deborah Conte Santos1, Marcela Haas Pizarro1, Laura Gomes Nunes Melo1, Bianca Senger Vasconcelos Barros1, Renan Montenegro2, Virginia Fernandes2, Carlos Antonio Negrato3.   

Abstract

AIMS: To evaluate the relationship between social determinants, health care insurance status and occurrence of diabetes-related chronic complications (DRCC) in Brazilian patients with type 1 diabetes.
METHODS: A multicenter cross-sectional study conducted between August 2011 and August 2014 in 14 public clinics in 10 Brazilian cities. Data were obtained from 1760 patients, aged 29.9 ± 11.9 years, with diabetes duration of 15.5 ± 9.3 years; 55.9% female, 54.5% Caucasians, 69.7% were attended exclusively by the public Brazilian National Health Care System (BNHCS) and 30.3% had also private health care insurance. Patients' information was obtained through a questionnaire and a chart review form.
RESULTS: The social determinants associated with having both private and public health care insurance were being employed, belonging to medium or high socioeconomic status, having more years of school attendance and having younger age. Regarding DRCC, patients that had private and public health care had lower rates of diabetic retinopathy and of any other DRCC. Chronic kidney disease was not associated with health care coverage status after adjusting for classical clinical risk factors.
CONCLUSIONS: Brazilian patients with type 1 diabetes had better clinical control and lower rates of DRCC, mainly retinopathy, when also having private health care insurance. These patients presented less frequently predictors of chronic complications such as high levels of HbA1c and blood pressure. BNHCS should change the approach for screening DRCC such as diabetic retinopathy, using methods such as telemedicine that would lead to earlier diagnosis, better outcomes and will be cost-effective sometime after its implementation.

Entities:  

Keywords:  Health care insurance; Microvascular chronic complications; Retinopathy; Type 1 diabetes

Mesh:

Year:  2019        PMID: 30868316     DOI: 10.1007/s00592-019-01308-7

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  4 in total

1.  Relationship among health-related quality of life and global ancestry, clinical and socioeconomic factors in type 1 diabetes in an admixed Brazilian population.

Authors:  Rossana Sousa Azulay; Débora Lago; Glaucia Abreu Silva Santos; Maria da Glória Tavares; Vandilson Rodrigues; Marcelo Magalhaês; Roberta Ferreira Reis; Nayara Nunes; Ana Gregória Ferreira Pereira Almeida; Adriana Guimarães Sá; Gilvan Nascimento; Sabrina Damianse; Viviane Rocha; Dayse Aparecida Silva; Marília Brito Gomes; Manuel Faria
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

2.  Therapeutic play to teach children with type 1 diabetes insulin self-injection: A pilot trial in a developing country.

Authors:  Rebecca O La Banca; Lori M B Laffel; Lisa K Volkening; Valéria C Sparapani; Emilia C de Carvalho; Lucila C Nascimento
Journal:  J Spec Pediatr Nurs       Date:  2020-09-18       Impact factor: 1.260

3.  The Association between Social Determinants of Health and Self-Reported Diabetic Retinopathy: An Exploratory Analysis.

Authors:  Emily L Silverberg; Trevor W Sterling; Tyler H Williams; Grettel Castro; Pura Rodriguez de la Vega; Noël C Barengo
Journal:  Int J Environ Res Public Health       Date:  2021-01-18       Impact factor: 3.390

4.  Comparison of three insulin bolus calculators to increase time in range of glycemia in a group of poorly controlled adults Type 1 diabetes in a Brazilian public health service.

Authors:  Vanessa Araujo Montanari; Mônica Andrade Lima Gabbay; Sérgio Atala Dib
Journal:  Diabetol Metab Syndr       Date:  2022-09-13       Impact factor: 5.395

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.